tradingkey.logo

BRIEF-Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer

ReutersFeb 19, 2025 3:22 PM

- Imunon Inc IMNN.O:

  • IMUNON ANNOUNCES TRANSLATIONAL DATA FROM PHASE 1/2 OVATION 2 STUDY OF IMNN-001 IN ADVANCED OVARIAN CANCER

  • IMUNON INC - IMNN-001 SHOWS FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS

  • IMUNON INC - TO INITIATE PHASE 3 TRIAL OF IMNN-001 IN Q1 2025

Source text: ID:nGNXrlPq5

Further company coverage: IMNN.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI